RxDoctor Payments Data

Jeffrey Bennion, MD

Plastic Surgery within the Head & Neck · North Logan, UTNPI 1396731469

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Medtronic at 47.1% of the total. Reporting peaked in 2020 at $731 and has fallen 92.7% since, to $53 in 2024.

$1,637in general payments, 2019–2025

Across 46 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$771
  • Sanofi$200
  • Regeneron Healthcare Solutions, Inc.$197
  • AstraZeneca$103
  • AbbVie$82
  • Carestream Dental, LLC$73
  • plus $211 from 8 others
$1,250in research payments, 2019–2025

Across 2 payments — averaging $625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intersect ENT, Inc.$1K

What the payments were for

  • Travel & lodging$70143%
  • Food & beverage$93657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic surgery within the head & neck providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$67,940
Medicare patients
268
Services billed
1,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,913
Lansoprazole114$2,756
SynthroidLevothyroxine Sodium24$1,309
Liothyronine Sodium36$1,119
Pantoprazole Sodium49$727
Levothyroxine Sodium66$603
CefuroximeCefuroxime Axetil33$525
Fluconazole28$406
Omeprazole22$393
Doxycycline Hyclate30$391
Clarithromycin12$390
Mupirocin47$381
Ondansetron OdtOndansetron27$301
Fluticasone Propionate20$251
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$82$1,30924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few plastic surgery within the head & neck providers in Utahon file to place this against a meaningful peer group, so we don't.

Other plastic surgery within the head & neck in North Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →